Iambic Therapeutics
Iambic Therapeutics: Pioneering AI-driven drug discovery with a fast, diverse, and high-quality therapeutics pipeline.
Founded
2019Iambic Therapeutics: Pioneering AI-driven drug discovery with a fast, diverse, and high-quality therapeutics pipeline.
Founded with the mission to revolutionize drug discovery, Iambic Therapeutics leverages advanced machine learning to expedite the development of high-quality therapeutics. The company combines the expertise of leading AI specialists and seasoned drug developers to create a robust platform capable of addressing various target classes and mechanisms of action. Their AI-driven software accelerates research and development, aiming to bring differentiated therapeutics to the clinic faster than traditional methods.
Iambic Therapeutics boasts a team of notable experts in artificial intelligence and pharmaceutical research, contributing to its innovative edge. The company has garnered attention for its ability to deliver clinically validated therapeutics with unprecedented speed. By integrating physics-based AI algorithms into their high-throughput experimental platform, Iambic has significantly impacted the drug discovery process, offering new molecular designs and biological insights on a weekly basis.
Companies similar to Iambic Therapeutics include Seismic Therapeutic, Terray Therapeutics, Numerion Labs and DeepCure.
Iambic Therapeutics was founded in 2019.
Iambic Therapeutics' headquarters is located in San Diego, CA, US.
Iambic Therapeutics' most recent funding round was for $100M (USD) in October 2023.
As of Oct 3, 2023, Iambic Therapeutics has disclosed funding of $153M (USD). Undisclosed round amounts are excluded.
Iambic Therapeutics has 75 employees as of Feb 5, 2024.
DeepCure
deepcure.ai
